Jul 13, 2022 7:15am EDT NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director
Jul 01, 2022 7:23am EDT FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir
Jun 23, 2022 7:45am EDT NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
Jun 10, 2022 10:47pm EDT NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)
Jun 07, 2022 8:02pm EDT NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer
May 26, 2022 12:03am EDT NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19
May 19, 2022 7:20am EDT NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference
May 16, 2022 7:12am EDT NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 12, 2022 8:17am EDT NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality
